CUSIP 514766104 · who reports it, how much, and how much it matters to them
14 of the 720 hedge fund managers we track reported shares of Lifecore Biomedical, Inc. (Nasdaq: LFCR) on Form 13F for 30 June 2026. Between them they reported USD 70m. The largest position belongs to Wynnefield Capital, at USD 25m. The manager with the most riding on it is Legion Partners Asset Management, where it is 57.8% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Wynnefield Capital3 funds on PPLI.com | USD 25m | 17.0% |
| 2 | Legion Partners Asset Management10 funds on PPLI.com | USD 23m | 57.8% |
| 3 | Greenhaven Road Investment Management4 funds on PPLI.com | USD 17m | 10.9% |
| 4 | Marshall Wace LLP84 funds on PPLI.com | USD 932,000 | 0.0% |
| 5 | Millennium Management6 funds on PPLI.com | USD 700,000 | 0.0% |
| 6 | Renaissance Technologies13 funds on PPLI.com | USD 551,000 | 0.0% |
| 7 | Grizzlyrock Capital2 funds on PPLI.com | USD 541,000 | 0.4% |
| 8 | Citadel Advisors32 funds on PPLI.com | USD 519,000 | 0.0% |
| 9 | Squarepoint Ops7 funds on PPLI.com | USD 487,000 | 0.0% |
| 10 | Gamco Asset Management1 fund on PPLI.com | USD 440,000 | 0.0% |
| 11 | POINT72 Asset Management17 funds on PPLI.com | USD 276,000 | 0.0% |
| 12 | Boothbay Fund Management2 funds on PPLI.com | USD 161,000 | 0.0% |
| 13 | Engineers Gate Manager1 fund on PPLI.com | USD 54,075 | 0.0% |
| 14 | 22NW1 fund on PPLI.com | USD 6,220 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Legion Partners Asset Management | USD 23m | 57.8% |
| 2 | Wynnefield Capital | USD 25m | 17.0% |
| 3 | Greenhaven Road Investment Management | USD 17m | 10.9% |
| 4 | Grizzlyrock Capital | USD 541,000 | 0.4% |
| 5 | 22NW | USD 6,220 | 0.0% |
| 6 | Gamco Asset Management | USD 440,000 | 0.0% |
| 7 | Boothbay Fund Management | USD 161,000 | 0.0% |
| 8 | Marshall Wace LLP | USD 932,000 | 0.0% |
| 9 | Renaissance Technologies | USD 551,000 | 0.0% |
| 10 | Squarepoint Ops | USD 487,000 | 0.0% |
Lifecore Biomedical, Inc. trades under the symbol LFCR on the Nasdaq. Its CUSIP, the code used on Form 13F, is 514766104.
14 of the 720 hedge fund managers PPLI.com tracks reported Lifecore Biomedical, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Wynnefield Capital (USD 25m), Legion Partners Asset Management (USD 23m), Greenhaven Road Investment Management (USD 17m), Marshall Wace LLP (USD 932,000) and Millennium Management (USD 700,000).
14 managers in our coverage reported it, and between them they run 183 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Legion Partners Asset Management, where the position was 57.8% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Lifecore Biomedical, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.